Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Ovid Therapeutics Inc.

Ovid Therapeutics develops targeted small molecule therapies to address neurological diseases, focusing on reducing seizures and improving safety and tolerability. The company aims to pioneer effective new treatments for epilepsies and brain conditions.

NASDAQ:OVID

Ovid Therapeutics

Last Close

1.30

08/11 21:00

Market Cap

62.01M

Beta: 1.13

Volume Today

146.68K

Avg: 84.82K

PE Ratio

0.17

PFCF: −5.90

locale

market

industry

website

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics